Skip to content
DraconiticResearch
Search Sources API
197,688 studies31 sourcesUpdated 11 min ago
Peer-reviewedCC BY 4.0Reviews in Cardiovascular Medicine

Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for the Treatment of Large De Novo Coronary Lesions

  • Wenjie Wang1
  • Hongfei Si2
  • Lingjuan Li3
  • Xiliang Zhao1
  • Quan Li1
  • Yong Zeng1
  • Xianpeng Yu1
  1. 1Department of Cardiology, Beijing AnZhen Hospital, Capital Medical University, 100069 Beijing, China
  2. 2Department of Cardiology, Dong’e People’s Hospital, 252299 Liaocheng, Shandong, China
  3. 3Department of Cardiology, Langfang Fourth People’s Hospital, 065700 Langfang, Hebei, China
Read full textPDFDOICite

Abstract

Background:: Although drug-coated balloons (DCBs) outperform drug-eluting stents (DESs) in the treatment of de novo small-vessel coronary lesions, no comparable studies are available for de novo large-vessel coronary lesions.

Methods:: This retrospective study examined 960 patients with de novo large-vessel coronary lesions (reference vessel diameter ≥3.0 mm) who underwent paclitaxel DCB angioplasty or DES implantation at Beijing Anzhen Hospital. The study endpoints included all-cause death, myocardial infarction (MI), stroke, and target vessel revascularization (TVR). Kaplan–Meier (KM) curves and Cox regression analysis were used to investigate the clinical outcomes of patients in the DCB and DES groups.

Results:: The overall incidence rates of major adverse cardiac and cerebrovascular events (MACCEs), all-cause death, MI, stroke, and TVR were 9.27% (89/960), 1.5% (14 patients), 0.9% (9 patients), 0.6% (6 patients), and 6.8% (65 patients), respectively. No significant differences were observed between the DCB and DES groups in MACCEs (13.2% vs. 5.6%; p = 0.511), all-cause death (1.9% vs. 1.0%; p = 0.763), MI (0.6% vs. 1.2%; p = 0.239), or stroke (0.6% vs. 0.6%; p = 0.361). However, the TVR rate was significantly higher in the DCB group than in the DES group (10.1% vs. 3.6%; p = 0.028), and this difference persisted after multivariate adjustment.

Conclusions:: For patients with de novo lesions in target vessels with diameters ≥3.0 mm, the safety and efficacy of DCB therapy were comparable to those of DES therapy, except for target vessel revascularization.

Related

  1. Sirolimus-Eluting Balloon With Provisional Stenting Versus Systematic Drug-Eluting Stent Implantation to Treat De Novo Coronary Lesions: A Randomized, Open-Label, Noninferiority Trial
    Christian M. Spaulding, Florian Krackhardt, Kris Bogaerts +82
    CirculationPeer-reviewedLicence not stated26 citedCardiovascular medicineSurgery & anaesthesiaOpenAlex
  2. Non-inferiority of a paclitaxel-coated balloon versus a rapamycin-eluting metal stent for de novo non-complex small coronary vessel disease: a prospective randomized controlled trial
    XiaoYu Xu, Yi Xiang, KangHui Ge +3
    Postepy w kardiologii interwencyjnej = Advances in interventional cardiologyPeer-reviewedCC BY-NC-SAFull textSurgery & anaesthesiaEurope PMCPMC
  3. Intravascular Imaging-Guided Drug-Eluting Stenting for Complex Coronary Lesions: A Meta-Analysis of Randomized Controlled Trials.
    Mohammed A Elbahloul, Bahaa El Deen Wehbeh, Ahmed Samy Badran +6
    JACC. AdvancesPeer-reviewedCC BYFull textSurgery & anaesthesiaEurope PMC
  4. Achieved LDL-C Levels and Clinical Outcomes Following Percutaneous Coronary Intervention with Drug-Coated Balloons for De Novo Coronary Lesions
    Takashi Nagasaka, Shunichiro Ishio, Ryota Taniuchi +4
    Journal of Atherosclerosis and ThrombosisPeer-reviewedLicence not statedFull textCardiovascular medicineJ-STAGE
  5. Balancing innovation and safety in percutaneous treatment of coronary artery calcification: the evolving role of cutting balloon technology
    Pierre Chenard, Claudiu Ungureanu, Giuseppe Colletti +5
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Cardiovascular medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{wang2026outcomes,
  title = {{Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for the Treatment of Large De Novo Coronary Lesions}},
  author = {Wenjie Wang and Hongfei Si and Lingjuan Li and Xiliang Zhao and Quan Li and Yong Zeng and Xianpeng Yu},
  journal = {Reviews in Cardiovascular Medicine},
  year = {2026},
  month = oct,
  doi = {10.31083/rcm50502},
  url = {https://doi.org/10.31083/rcm50502},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Outcomes of Drug-Coated Balloon Versus Drug-Eluting Stent for the Treatment of Large De Novo Coronary Lesions
AU  - Wenjie Wang
AU  - Hongfei Si
AU  - Lingjuan Li
AU  - Xiliang Zhao
AU  - Quan Li
AU  - Yong Zeng
AU  - Xianpeng Yu
PY  - 2026
DA  - 2026/10/12
JO  - Reviews in Cardiovascular Medicine
DO  - 10.31083/rcm50502
UR  - https://doi.org/10.31083/rcm50502
AB  - Background:: Although drug-coated balloons (DCBs) outperform drug-eluting stents (DESs) in the treatment of de novo small-vessel coronary lesions, no comparable studies are available for de novo large-vessel coronary lesions.  Methods:: This retrospective study examined 960 patients with de novo large-vessel coronary lesions (reference vessel diameter ≥3.0 mm) who underwent paclitaxel DCB angioplasty or DES implantation at Beijing Anzhen Hospital. The study endpoints included all-cause death, myocardial infarction (MI), stroke, and target vessel revascularization (TVR). Kaplan–Meier (KM) curves and Cox regression analysis were used to investigate the clinical outcomes of patients in the DCB and DES groups.  Results:: The overall incidence rates of major adverse cardiac and cerebrovascular events (MACCEs), all-cause death, MI, stroke, and TVR were 9.27% (89/960), 1.5% (14 patients), 0.9% (9 patients), 0.6% (6 patients), and 6.8% (65 patients), respectively. No significant differences were observed between the DCB and DES groups in MACCEs (13.2% vs. 5.6%; p = 0.511), all-cause death (1.9% vs. 1.0%; p = 0.763), MI (0.6% vs. 1.2%; p = 0.239), or stroke (0.6% vs. 0.6%; p = 0.361). However, the TVR rate was significantly higher in the DCB group than in the DES group (10.1% vs. 3.6%; p = 0.028), and this difference persisted after multivariate adjustment.  Conclusions:: For patients with de novo lesions in target vessels with diameters ≥3.0 mm, the safety and efficacy of DCB therapy were comparable to those of DES therapy, except for target vessel revascularization.
SN  - 1530-6550
SN  - 2153-8174
ER  -